-
1
Moe S, et al.. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945–1953.
-
2
Sprague SM. Renal bone disease. Curr Opin Endocrinol Diabetes Obes 2010; 17:535–539.
-
3
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1–S130.
-
4
Palmer SC, et al.. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305:1119–1127.
-
5
Uhlig K. What should a guideline panel do when evidence is inconclusive? The case of treatments for CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2011; 58:872–875.
-
6
Uhlig K, et al.. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55:773–799.
-
7
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 Suppl 3):S1–S201.
Highlights of the KDIGO Bone and Mineral Disorder Guidelines
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory